

Global Curative Therapeutics Market - 2025 -2033

<https://marketpublishers.com/r/G74C37BED156EN.html>

Date: October 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G74C37BED156EN

Abstracts

Market Size

The global curative therapeutics market size reached US\$ 19.94 Billion in 2024 from US\$ 18.34 Billion in 2023 and is expected to reach US\$ 44.95 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Market Overview

The curative therapeutics market is emerging as one of the most transformative segments in modern medicine, driven by therapies designed to correct or permanently resolve the underlying cause of disease rather than manage symptoms. It encompasses biology-modifying drugs, gene therapies, and genetically engineered cell therapies that offer the potential for one-time interventions with long-lasting or lifelong benefits. Oncology remains the largest application area, especially through CAR-T and other advanced cell therapies, while rare genetic disorders and certain infectious diseases represent fast-growing opportunities. Despite challenges related to affordability, durability of effect, and access, the sector is expected to remain a strategic focus for industry stakeholders, given its potential to redefine standards of care and deliver curative outcomes across multiple disease areas.

Curative Therapeutics Market Dynamics

Drivers:

Growing recognition for rare and orphan diseases is significantly driving the curative therapeutics market growth

The growing recognition of rare and orphan diseases is one of the most significant

drivers of the curative therapeutics market, as it creates both an urgent medical need and a supportive policy environment for innovation. Rare diseases, by definition, affect small patient populations, yet collectively they represent millions of individuals worldwide who often lack effective treatment options. For many of these conditions, traditional therapies provide only symptomatic relief, whereas curative approaches such as gene and cell therapies can directly target the genetic or molecular root cause. This alignment of unmet need with scientific feasibility has made orphan diseases a natural entry point for curative technologies.

Regulatory agencies have amplified this momentum by offering orphan drug designations and fast-track approvals to developers working in this space. For instance, Novartis's Zolgensma, approved for spinal muscular atrophy, and bluebird bio's Zynteglo for beta-thalassemia, demonstrate how gene therapies can achieve transformative clinical outcomes in previously untreatable populations. Beyond these high-profile cases, curative pipelines are expanding into hemophilia, sickle cell disease, and inherited retinal disorders, with each success story reinforcing investor and payer confidence.

Restraints:

High upfront therapy costs and affordability concerns are hampering the growth of the curative therapeutics market

High upfront therapy costs and affordability concerns remain one of the most pressing restraints on the curative therapeutics market, as they create significant barriers for patients, healthcare systems, and payers. Unlike traditional treatments that spread costs over time, many curative therapies are priced in the range of hundreds of thousands to millions of dollars for a single administration, creating what is often termed a "sticker shock" effect.

For instance, Novartis's gene therapy Zolgensma for spinal muscular atrophy is priced at over \$2.1 million, making it one of the most expensive treatments globally, while bluebird bio's Zynteglo for beta-thalassemia carries a price tag of \$2.8 million in the U.S. Although these therapies can offer lifelong benefits and offset the costs of chronic care, payers face challenges in absorbing such high upfront expenditures within annual budgets. This issue is particularly pronounced in countries with fragmented healthcare systems or limited insurance coverage, where access is restricted to only a fraction of eligible patients.

Affordability concerns exacerbate health inequities, as patients in low- and middle-income countries are largely excluded from access to these life-changing interventions. The result is a paradox, while curative therapeutics promise to revolutionize healthcare by addressing the root causes of diseases, their high price points slow adoption, limit reimbursement, and raise ethical concerns about who can truly benefit. Until scalable manufacturing, innovative financing models, and broader payer acceptance are established, high upfront costs will continue to be a major hurdle restraining market growth.

Segmentation Analysis

The global curative therapeutics market is segmented based on therapy type, indication, end-user, and region.

The oncology segment from the indication is dominating the curative therapeutics market with a 22.31% share in 2024

Oncology represents the dominant segment in the curative therapeutics market, largely due to the high global burden of cancer, the urgent need for transformative therapies, and the remarkable clinical successes achieved with advanced modalities such as CAR-T cell therapies and gene editing. Cancer remains one of the leading causes of mortality worldwide, with an expected 35.3 million incidence cases by 2050 according to the WHO, driving into innovative solutions that can move beyond palliative or maintenance care toward long-term remission or cure. The approval of CAR-T therapies like Novartis's Kymriah and Gilead's Yescarta for hematologic malignancies has demonstrated the potential of curative approaches, achieving durable remissions in patients who previously had limited or no treatment options.

Major and emerging market players are offering cost-effective solutions, further driving the growth of the market. For instance, in January 2025, Immuneel Therapeutics launched India's second CAR-T cell therapy, Qartemi, to treat patients with B-cell Non-Hodgkin Lymphoma (B-NHL), an aggressive form of blood cancer, at less than one-tenth of the price of similar therapies available in Western countries. The results showed that the efficacy and safety of Qartemi are similar to CAR T-cell therapies approved by the US FDA.

Geographical Share Analysis

North America is expected to dominate the global curative therapeutics market with a

42.31% in 2024

North America stands as the dominant region in the global curative therapeutics market, driven by its strong research ecosystem, favorable regulatory framework, and high levels of investment in advanced therapies. The United States, in particular, has pioneered the approval and commercialization of many landmark curative products. For instance, the FDA approved Novartis's Zolgensma for spinal muscular atrophy and bluebird bio's Zynteglo for beta-thalassemia, both of which are considered breakthroughs in gene therapy.

Similarly, in April 2024, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved BEQVEZ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.

The region leads in cell-based curative treatments, with CAR-T therapies like Kymriah and Yescarta rapidly gaining traction across oncology centers of excellence. Canada is also progressing in this space, with Health Canada streamlining frameworks for advanced therapy medicinal products. Collectively, the combination of scientific leadership, regulatory support, and clinical adoption cements North America's position as the dominant market for curative therapeutics, setting benchmarks that other regions are striving to emulate.

Competitive Landscape

Top companies in the curative therapeutics market include Gilead Sciences, Inc., Spark Therapeutics, Inc., Pfizer Inc., Amgen, Inc., Novartis Pharmaceuticals Corporation, bluebird bio, Inc. and Sarepta Therapeutics, Inc., among others.

Key Developments

In May 2025, Sarepta Therapeutics, Inc. announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals aged 3 to less than 8 years old, who do not have any

deletions in exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. This is the first global approval to include individuals younger than 4 years of age.

In February 2025, CSL Behring announced the four-year results from the pivotal HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX (etranacogene dezaparvovec-drlb) gene therapy for adults living with hemophilia B.

The global curative therapeutics market report delivers a detailed analysis with 53 key tables, more than 56 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Therapy Type
- 2.4. Snippet by Indication
- 2.5. Snippet by End-User
- 2.6. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Growing Recognition for Rare and Orphan Diseases
 - 3.1.1.2. Evolving Reimbursement Models for High-Value Therapies
 - 3.1.2. Restraints
 - 3.1.2.1. High Upfront Therapy Costs and Affordability Concerns
 - 3.1.2.2. Complex Manufacturing and Supply Chain Bottlenecks
 - 3.1.3. Opportunity
 - 3.1.3.1. In-vivo Gene Editing and Non-viral Delivery
 - 3.1.3.2. Curative Combos and Sequencing
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape

- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Patent Analysis
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics

5. CURATIVE THERAPEUTICS MARKET, BY THERAPY TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
 - 5.1.2. Market Attractiveness Index, By Therapy Type
- 5.2. Biology-Modifying Drugs*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Gene Therapies
- 5.4. Cell Therapies
- 5.5. Others

6. CURATIVE THERAPEUTICS MARKET, BY INDICATION

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 6.1.2. Market Attractiveness Index, By Indication
- 6.2. Oncology*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Rare Genetic Disorders
- 6.4. Infectious Diseases
- 6.5. Hematology
- 6.6. Ophthalmology
- 6.7. Neurology
- 6.8. Cardiometabolic Disorders
- 6.9. Others

7. CURATIVE THERAPEUTICS MARKET, BY END-USER

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

7.1.2. Market Attractiveness Index, By End-User

7.2. Hospitals*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Specialty Clinics

7.4. Academic and Research Institutes

7.5. Others

8. CURATIVE THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

8.1.2. Market Attractiveness Index, By Region

8.2. North America

8.2.1. Introduction

8.2.2. Key Region-Specific Dynamics

8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.2.6.1. U.S.

8.2.6.2. Canada

8.2.6.3. Mexico

8.3. Europe

8.3.1. Introduction

8.3.2. Key Region-Specific Dynamics

8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.6.1. Germany

8.3.6.2. UK

8.3.6.3. France

8.3.6.4. Spain

8.3.6.5. Italy

8.3.6.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. China

8.4.6.2. India

8.4.6.3. Japan

8.4.6.4. South Korea

8.4.6.5. Rest of Asia-Pacific

8.5. South America

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.5.6.1. Brazil

8.5.6.2. Argentina

8.5.6.3. Rest of South America

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

9.1. Competitive Overview and Key Market Players

9.2. Market Share Analysis and Positioning Matrix

9.3. Strategic Partnerships, Mergers & Acquisitions

9.4. Key Developments in Product Portfolios and Innovations

9.5. Company Benchmarking

10. COMPANY PROFILES

- 10.1. Gilead Sciences, Inc.*
 - 10.1.1. Company Overview
 - 10.1.2. Product Portfolio
 - 10.1.2.1. Product Description
 - 10.1.2.2. Product Key Performance Indicators (KPIs)
 - 10.1.3. Financial Overview
 - 10.1.3.1. Company Revenue
 - 10.1.3.2. Geographical Revenue Shares
 - 10.1.3.3. Revenue Forecasts
 - 10.1.4. Key Developments
 - 10.1.4.1. Mergers & Acquisitions
 - 10.1.4.2. Key Product Development Activities
 - 10.1.4.3. Regulatory Approvals, etc.
 - 10.1.4.4. SWOT Analysis
- 10.2. Spark Therapeutics, Inc.
- 10.3. Pfizer Inc.
- 10.4. Amgen, Inc.
- 10.5. Novartis Pharmaceuticals Corporation
- 10.6. bluebird bio, Inc.
- 10.7. Sarepta Therapeutics, Inc. (LIST NOT EXHAUSTIVE)

11. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques
- 11.4. Data Verification and Validation

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 Global Curative Therapeutics Market Value, By Therapy Type, 2025, 2029 & 2033 (US\$ Billion)

Table 2 Global Curative Therapeutics Market Value, By Indication, 2025, 2029 & 2033 (US\$ Billion)

Table 3 Global Curative Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US\$ Billion)

Table 4 Global Curative Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 5 Global Curative Therapeutics Market Value, By Therapy Type, 2025, 2029 & 2033 (US\$ Billion)

Table 6 Global Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US\$ Billion)

Table 7 Global Curative Therapeutics Market Value, By Indication, 2025, 2029 & 2033 (US\$ Billion)

Table 8 Global Curative Therapeutics Market Value, By Indication, 2022-2033 (US\$ Billion)

Table 9 Global Curative Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US\$ Billion)

Table 10 Global Curative Therapeutics Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 11 Global Curative Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 12 Global Curative Therapeutics Market Value, By Region, 2022-2033 (US\$ Billion)

Table 13 North America Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US\$ Billion)

Table 14 North America Curative Therapeutics Market Value, By Indication, 2022-2033 (US\$ Billion)

Table 15 North America Curative Therapeutics Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 16 North America Curative Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 17 Europe Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US\$ Billion)

Table 18 Europe Curative Therapeutics Market Value, By Indication, 2022-2033 (US\$ Billion)

Billion)

Table 19 Europe Curative Therapeutics Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 20 Europe Curative Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 21 Asia-Pacific Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US\$ Billion)

Table 22 Asia-Pacific Curative Therapeutics Market Value, By Indication, 2022-2033 (US\$ Billion)

Table 23 Asia-Pacific Curative Therapeutics Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 24 Asia-Pacific Curative Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 25 South America Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US\$ Billion)

Table 26 South America Curative Therapeutics Market Value, By Indication, 2022-2033 (US\$ Billion)

Table 27 South America Curative Therapeutics Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 28 South America Curative Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 29 Middle East and Africa Curative Therapeutics Market Value, By Therapy Type, 2022-2033 (US\$ Billion)

Table 30 Middle East and Africa Curative Therapeutics Market Value, By Indication, 2022-2033 (US\$ Billion)

Table 31 Middle East and Africa Curative Therapeutics Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 32 Middle East and Africa Curative Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 33 Gilead Sciences, Inc.: Overview

Table 34 Gilead Sciences, Inc.: Product Portfolio

Table 35 Gilead Sciences, Inc.: Key Developments

Table 36 Spark Therapeutics, Inc.: Overview

Table 37 Spark Therapeutics, Inc.: Product Portfolio

Table 38 Spark Therapeutics, Inc.: Key Developments

Table 39 Pfizer Inc.: Overview

Table 40 Pfizer Inc.: Product Portfolio

Table 41 Pfizer Inc.: Key Developments

Table 42 Amgen, Inc.: Overview

Table 43 Amgen, Inc.: Product Portfolio

Table 44 Amgen, Inc.: Key Developments

Table 45 Novartis Pharmaceuticals Corporation: Overview

Table 46 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 47 Novartis Pharmaceuticals Corporation: Key Developments

Table 48 bluebird bio, Inc.: Overview

Table 49 bluebird bio, Inc.: Product Portfolio

Table 50 bluebird bio, Inc.: Key Developments

Table 51 Sarepta Therapeutics, Inc.: Overview

Table 52 Sarepta Therapeutics, Inc.: Product Portfolio

Table 53 Sarepta Therapeutics, Inc.: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 2 Global Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)

Figure 3 Global Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)

Figure 4 Global Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)

Figure 5 Global Curative Therapeutics Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Curative Therapeutics Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)

Figure 7 Biology-Modifying Drugs Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 8 Gene Therapies Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 9 Cell Therapies Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 10 Others Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 11 Global Curative Therapeutics Market Y-o-Y Growth, By Indication, 2023-2033 (%)

Figure 12 Oncology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 13 Rare Genetic Disorders Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 14 Infectious Diseases Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 15 Hematology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 16 Ophthalmology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 17 Neurology Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 18 Cardiometabolic Disorders Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 19 Others Indication in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 20 Global Curative Therapeutics Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 21 Hospitals End-User in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 22 Specialty Clinics End-User in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 23 Academic and Research Institutes End-User in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 24 Others End-User in Global Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 25 Global Curative Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 26 North America Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 27 North America Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)

Figure 28 North America Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)

Figure 29 North America Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)

Figure 30 North America Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 31 Europe Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 32 Europe Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)

Figure 33 Europe Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)

Figure 34 Europe Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)

Figure 35 Europe Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 36 Asia-Pacific Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 37 Asia-Pacific Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)

Figure 38 Asia-Pacific Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)

Figure 39 Asia-Pacific Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)

Figure 40 Asia-Pacific Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 41 South America Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 42 South America Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)

Figure 43 South America Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)

Figure 44 South America Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)

Figure 45 South America Curative Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 46 Middle East and Africa Curative Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 47 Middle East and Africa Curative Therapeutics Market Share, By Therapy Type, 2024 & 2033 (%)

Figure 48 Middle East and Africa Curative Therapeutics Market Share, By Indication, 2024 & 2033 (%)

Figure 49 Middle East and Africa Curative Therapeutics Market Share, By End-User, 2024 & 2033 (%)

Figure 50 Gilead Sciences, Inc.: Financials

Figure 51 Spark Therapeutics, Inc.: Financials

Figure 52 Pfizer Inc.: Financials

Figure 53 Amgen, Inc.: Financials

Figure 54 Novartis Pharmaceuticals Corporation: Financials

Figure 55 bluebird bio, Inc.: Financials

Figure 56 Sarepta Therapeutics, Inc.: Financials

I would like to order

Product name: Global Curative Therapeutics Market - 2025 -2033

Product link: <https://marketpublishers.com/r/G74C37BED156EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G74C37BED156EN.html>